Efficacy of Lenvatinib

Lenvatinib is more effective than placebo, a dummy treatment, in slowing disease progression, a major study shows. The study involved 392 adult patients with differentiated thyroid cancer (DTC) who had shown signs of progression in the previous year and had not responded to radioactive iodine treatment. The main measure of effectiveness was how long patients lived without their disease getting worse: Patients who took lenvatinib lived an average of 18.3 months, compared with 3.6 months for those who took a placebo.

Lenvatinib is at least as effective as the cancer drug sorafenib in extending patients' survival, a major study suggests. The study involved 954 patients with hepatocellular carcinoma (HCC) who had not received previous cancer treatment and whose cancer could not be removed with surgery. Patients who received lenvatinib lived on average 13.6 months, while those who received sorafenib lived on average 12.3 months.

Lenvatinib is also approved as a combination drug with Everolimus based on a randomized Phase II trialCombination treatment of advanced renal cell carcinoma (RCC), The trial compared24 mg lenvatinib monotherapy with 5 mg everolimus monotherapy, and 24 mg lenvatinib and 5 mg everolimus in combination. Progression-free survival (PFS) for patients treated with the combination was 14.6 months, compared with 5.5 months for patients treated with everolimus alone. The combination regimen reduced the risk of disease progression or death by 63% compared with everolimus alone. The objective response rate for patients treated with the combination regimen was 37%, compared with 6% for patients treated with everolimus alone. Patients treated with LEN+EVE had a median overall survival (OS) increase of 10.1 months compared with patients treated with everolimus alone.

Lenvatinib plus pembrolizumab was shown to be more effective than standard treatment in a major study involving827 patients with endometrial cancer (EC) whose disease worsened after platinum-based treatment. The average survival time of patients who received lenvatinib plus pembrolizumab was 18.3 months, and that of patients who received standard treatment was 11.4 months. The average survival time of patients without further disease progression was 7.2 months and 3.8 months respectively.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 800 (the price may fluctuate due to exchange rates).